SCHEMBL1789020

SCHEMBL1789020

CCC1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.58
GFER P55789 4/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
KDM4E B2RXH2 3/20 0.58
GAA P10253 3/20 0.58
RAD52 P43351 1/20 0.58
ALDH1A1 P00352 4/20 0.53
KMT2A Q03164 3/20 0.53
ADRA2C P18825 1/20 0.53
PTK2B Q14289 1/20 0.53
ESR2 Q92731 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.50
HTT P42858 2/20 0.50
MEN1 O00255 2/20 0.50
USP2 O75604 2/20 0.50
NPC1 O15118 1/20 0.50
TP53 P04637 1/20 0.50
POLB P06746 1/20 0.50
THRB P10828 1/20 0.50
ALOX15 P16050 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12045684 0.89 MAPT (0.50) MAPTGFERSMN1; SMN2KDM4EGAA
SCHEMBL25188789 0.86 MAPT (0.54) MAPTGFERSMN1; SMN2KDM4EGAA
SCHEMBL2608101 0.85 MAPT (0.53) MAPTGFERSMN1; SMN2KDM4EGAA
SCHEMBL149713 0.83 ADRB1 (0.50) MAPTSMN1; SMN2GAAALDH1A1KMT2A
SCHEMBL15651158 0.83 MAPT (0.52) MAPTGFERSMN1; SMN2KDM4EGAA
SCHEMBL25192949 0.83 MAPT (0.51) MAPTGFERSMN1; SMN2KDM4EGAA
SCHEMBL23483081 0.82 HRH3 (0.57) MAPTGFERSMN1; SMN2KDM4EGAA
SCHEMBL27679041 0.82 GPR119 (0.48) MAPTGFERSMN1; SMN2KDM4EGAA
SCHEMBL3440122 0.82 MAPT (0.50) MAPTGFERSMN1; SMN2KDM4EGAA
SCHEMBL3440272 0.82 GFER (0.50) MAPTGFERSMN1; SMN2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360114-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-10-31 US disclosed
CN-115151252-B Iron death inhibitor-diarylamine acetamides 维泰瑞隆有限公司 2024-08-27 CN disclosed
EP-4384493-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2024-06-19 EP disclosed
CN-118076581-A Iron death modulators, their preparation and use 维泰瑞隆有限公司 2024-05-24 CN disclosed
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES Sironax Ltd. (KY) 2023-05-25 US disclosed
WO-2023016447-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2023-02-16 WO disclosed
WO-2018043325-A1 LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME 日産化学工業株式会社 2018-03-08 WO disclosed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP disclosed
WO-2012018868-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-02-09 WO disclosed
EP-1761505-B1 PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-17 EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO disclosed
CN-100548985-C N-aryl piperidine substituted biphenylcarboxamides as apolipoprotein B inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-10-14 CN disclosed
CN-1890217-A N-aryl piperidine substituted biphenylcarboxamides as apolipoprotein B inhibitors JANSSEN PHARMACEUTICA NV (BE) 2007-01-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360114-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF AIFM2, GPX1, GPX4 MAPT 2954/4885GFER 1524/4885SMN1; SMN2 1343/4885
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 MAPT 2383/4885GFER 4726/4885SMN1; SMN2 2442/4885
US-20230159492-A1 FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES AIFM2, FECH, GPX4 MAPT 4384/4885GFER 505/4885SMN1; SMN2 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.